近年来斯坦福大学内科对慢性活动性肝炎(下称慢活肝)及携带者的治疗问题进行了研究。治疗不仅可使患者去除乙型肝炎病毒的感染,且可切断母婴传播途径和限制乙型肝炎的发生。在进行慢活肝临床治疗试验时,应选择具有稳定感染基础的慢性病毒携带者,治疗前数周或数月内可以看到 Dane 颗粒及 HBV-DNA 的存在。经抗病毒药物治疗后,观察 In recent years, Stanford University Internal Medicine chronic active hepatitis (hereinafter referred to as slow living liver) and carrier treatment problems were studied. Treatment not only allows patients to get rid of hepatitis B virus infection, but also cut off the mother-to-child transmission and limit the occurrence of hepatitis B. In clinical trials of slow-acting liver therapies should be selected for chronic virus carriers with a stable infection base. The presence of Dane particles and HBV-DNA can be seen within weeks or months of treatment. After treatment with antiviral drugs, observe